Šalis: Jungtinės Valstijos
kalba: anglų
Šaltinis: NLM (National Library of Medicine)
Sodium Nitroprusside (UNII: EAO03PE1TC) (Nitroprusside - UNII:169D1260KM)
Akorn
Sodium Nitroprusside
Sodium Nitroprusside 50 mg in 2 mL
INTRAVENOUS
PRESCRIPTION DRUG
Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. Sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. Sodium nitroprusside should not be used in the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting. Sodium nitroprusside should not be used to produce hypotension during surgery in patients with known inadequate cerebral circulation, or in moribund patients (A.S.A. Class 5E) coming to emergency surgery. Patients with congenital (Leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. These rare condition
Sodium Nitroprusside Injection is supplied in amber-colored, single-dose 50 mg/2 mL Fliptop Vials NDC 17478-014-02 2 mL Single-dose vial Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. To protect Sodium Nitroprusside Injection from light, it should be stored in its carton until it is used. Akorn Manufactured for: Akorn, Inc. Lake Forest, IL 60045 PC4952C Rev. 08/17
Abbreviated New Drug Application
SODIUM NITROPRUSSIDE- SODIUM NITROPRUSSIDE INJECTION, SOLUTION, CONCENTRATE AKORN ---------- SODIUM NITROPRUSSIDE INJECTION FLIPTOP VIAL Rx only SODIUM NITROPRUSSIDE INJECTION IS NOT SUITABLE FOR DIRECT INJECTION. THE SOLUTION MUST BE FURTHER DILUTED IN STERILE 5% DEXTROSE INJECTION BEFORE INFUSION. SODIUM NITROPRUSSIDE INJECTION CAN CAUSE PRECIPITOUS DECREASES IN BLOOD PRESSURE (SEE _DOSAGE AND ADMINISTRATION_). IN PATIENTS NOT PROPERLY MONITORED, THESE DECREASES CAN LEAD TO IRREVERSIBLE ISCHEMIC INJURIES OR DEATH. SODIUM NITROPRUSSIDE SHOULD BE USED ONLY WHEN AVAILABLE EQUIPMENT AND PERSONNEL ALLOW BLOOD PRESSURE TO BE CONTINUOUSLY MONITORED. EXCEPT WHEN USED BRIEFLY OR AT LOW (< 2 MCG/KG/MIN) INFUSION RATES, SODIUM NITROPRUSSIDE GIVES RISE TO IMPORTANT QUANTITIES OF CYANIDE ION, WHICH CAN REACH TOXIC, POTENTIALLY LETHAL LEVELS (SEE _WARNINGS_). THE USUAL DOSE RATE IS 0.5 TO 10 MCG/KG/MIN, BUT INFUSION AT THE MAXIMUM DOSE RATE SHOULD NEVER LAST MORE THAN 10 MINUTES. IF BLOOD PRESSURE HAS NOT BEEN ADEQUATELY CONTROLLED AFTER 10 MINUTES OF INFUSION AT THE MAXIMUM RATE, ADMINISTRATION OF SODIUM NITROPRUSSIDE SHOULD BE TERMINATED IMMEDIATELY. ALTHOUGH ACID-BASE BALANCE AND VENOUS OXYGEN CONCENTRATION SHOULD BE MONITORED AND MAY INDICATE CYANIDE TOXICITY, THESE LABORATORY TESTS PROVIDE IMPERFECT GUIDANCE. DESCRIPTION Sodium nitroprusside is disodium pentacyanonitrosylferrate(2-) dihydrate, a hypotensive agent whose structural formula is Sodium nitroprusside whose molecular formula is Na [Fe(CN) NO] • 2H O, and whose molecular weight is 297.95. Dry sodium nitroprusside is a reddish-brown powder, soluble in water. In an aqueous solution infused intravenously, sodium nitroprusside is a 2 5 2 rapid-acting vasodilator, active on both arteries and veins. Sodium nitroprusside solution is rapidly degraded by trace contaminants, often with resulting color changes. (See _DOSAGE AND ADMINISTRATION_ section.) The solution is also sensitive to certain wavelengths of light, and it must be protected from light in clinical use. S Perskaitykite visą dokumentą